Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a clinical trial of bisantrene RC220 in combination with oral decitabine/cedazuridine in dose escalation studies, followed by a triple combination with a standard of care treatment

Next Previous
Trial Profile

A Phase 1b/2a clinical trial of bisantrene RC220 in combination with oral decitabine/cedazuridine in dose escalation studies, followed by a triple combination with a standard of care treatment

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bisantrene (Primary) ; Cedazuridine/decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Race Oncology

Most Recent Events

  • 11 Aug 2023 New trial record
  • 08 Aug 2023 According to Race oncology media release, the company retains a solid cash reserve and this study is fully funded.
  • 08 Aug 2023 According to Race oncology media release, the trial is planned to start in late Q4 CY 2023, with transitional phases from RC110 to RC220 in 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top